<DOC>
	<DOCNO>NCT00516373</DOCNO>
	<brief_summary>To determine safety , tolerability , dose-limiting toxicity ( DLT ) , pharmacokinetic-pharmacodynamic profile , maximum tolerate dose ( MTD ) KU-0059436 administer orally patient advance solid tumour . To evaluate safety efficacy KU-0059436 expand cohort BCRA-enriched population , primarily ovarian cancer patient .</brief_summary>
	<brief_title>A Study Assess Safety Pharmacokinetics Inhibitor Poly ADP-Ribose Polymerase-1 ( PARP )</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<mesh_term>Poly ( ADP-ribose ) Polymerase Inhibitors</mesh_term>
	<criteria>Confirmed malignant advance solid tumour refractory standard therapy suitable effective standard therapy exist . Anticancer therapy include chemotherapy , radiotherapy , endocrine therapy , immunotherapy use investigational agent within 4 week prior trial entry ( long period depend defined characteristic agent use ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>advanced ovarian cancer</keyword>
	<keyword>BRCA 1 protein</keyword>
	<keyword>BRCA 2 protein</keyword>
	<keyword>Poly ( ADP ribose ) polymerase</keyword>
</DOC>